Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

623
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
623
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

453
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
453
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

119
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
119
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

608
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
608
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

1.3K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.3K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

91
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
91

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antiviral therapy and interleukin-6 blockade associated with lower thrombotic risk in hospitalized COVID-19: a target trial emulation.

Scientific reports·2026
Same author

Low prevalence of bacterial coinfection at hospital admission in COVID-19 and the role of procalcitonin as a rule-out biomarker (Revised Version).

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Quality of "on": a novel therapeutic objective in advanced Parkinson's disease.

Parkinsonism & related disorders·2026
Same author

Beyond Surveillance Mutations: Long-Term Trends and Clinical Relevance of Transmitted HIV Drug Resistance in Spain (2007-2023).

Open forum infectious diseases·2026
Same author

Hodgkin and non-Hodgkin lymphomas in the post-antiretroviral therapy era according to HIV virological suppression.

HIV medicine·2026
Same author

Contribution of hepatic steatosis to subclinical atherosclerosis progression in people with HIV receiving integrase inhibitors: A 5-Year prospective cohort study.

AIDS (London, England)·2026

Related Experiment Video

Updated: Dec 1, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

940

COVID-19-associated encephalitis successfully treated with combination therapy.

Eric Freire-Álvarez1, Lucía Guillén2, Karine Lambert3

  • 1Neurology Department, Hospital General Universitario de Elche, Alicante, Spain.

Clinical Infection in Practice
|November 9, 2020
PubMed
Summary
This summary is machine-generated.

Severe novel coronavirus disease (COVID-19) can cause acute encephalitis mimicking demyelinating conditions. Treatment with immunoglobulins and IL-6 blockade led to full recovery in a COVID-19 patient with encephalitis.

Keywords:
Acute demyelinating encephalomyelitisCOVID-19EncephalitisImmunoglobulinsSARS-CoV-2Tocilizumab

More Related Videos

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

18.6K
A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
06:54

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice

Published on: June 22, 2022

3.1K

Related Experiment Videos

Last Updated: Dec 1, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

940
Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

18.6K
A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
06:54

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice

Published on: June 22, 2022

3.1K

Area of Science:

  • Neurology
  • Infectious Diseases
  • Immunology

Background:

  • Acute encephalitis is a severe neurological condition linked to various viral infections and immune responses.
  • Severe COVID-19 is characterized by a significant inflammatory response, including elevated interleukin-6 (IL-6) levels.

Observation:

  • A 39-year-old male presented with symptoms of acute encephalitis, including drowsiness, disorientation, fever, and headache.
  • Brain MRI revealed extensive brain involvement. Cerebrospinal fluid analysis showed lymphocytic pleocytosis. SARS-CoV-2 was detected in nasopharyngeal swabs but not CSF.
  • Laboratory tests indicated a hyperinflammatory state with elevated ferritin, IL-6, and D-dimer.

Findings:

  • The patient required mechanical ventilation due to a complicated clinical course.
  • Treatment with intravenous immunoglobulins and tocilizumab (an IL-6 receptor antagonist) was initiated, considering acute demyelinating encephalomyelitis.
  • The patient achieved a full recovery, suggesting the encephalitis was related to the host's inflammatory response to SARS-CoV-2 infection.

Implications:

  • COVID-19 can manifest as an encephalitis syndrome that closely resembles acute demyelinating encephalomyelitis.
  • This case highlights the potential efficacy of immunomodulatory therapies, such as cytokine blockade, in managing COVID-19-associated encephalitis.